Fig. 5: Overview of cell viability and the synergistic effect between 2-drug combinations in four TNBC cell lines (CAL-148, HCC38, HCC1806, and MDA-MB-468) and three controls (BT-474, MCF-7, and T47D).
From: Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer
A The controls and HCC1806 cells were insensitive to the potent drug combination with bortezomib+nedaplatin. B All tested cell lines were insensitive to clinically relevant carboplatin+paclitaxel. C The combination with the highest synergy score was carboplatin + docetaxel on the CAL-148 cell line, achieving a synergy score of 36.7 at 32 µM/10 nM, respectively. D Bortezomib + nedaplatin on CAL-148 cell line had a synergy score of 19.7 at 625 nM/512 µM, respectively, and E epoxomicin + nedaplatin had a synergy score of 29.2 at 10 nM/32 µM, respectively. F Epirubicin + delanzomib showed an antagonistic score at all tested doses for MDA-MB-468. A synergy score ≥10 is considered to be strong synergy and ≤-10 as strong antagonism.
